Antibiotic Use in Pediatric Acute Pancreatitis
Introduction to Antibiotic Indications
- The World Society of Emergency Surgery recommends against routine prophylactic antibiotics in children with acute pancreatitis, regardless of severity, as they do not reduce mortality or morbidity 1, 2
- The American College of Gastroenterology suggests that prophylactic antibiotics are not recommended for patients with acute pancreatitis, including those with sterile necrosis, due to lack of benefit in well-designed trials 4, 1
Diagnostic Approach to Identify Infection
- Procalcitonin (PCT) is the most valuable serum marker for predicting infected pancreatic necrosis and should guide decision-making, according to the World Society of Emergency Surgery 1, 5, 2
- Gas in the retroperitoneal area on CT imaging is highly indicative of infected pancreatitis, although only present in a minority of cases, as noted by the World Society of Emergency Surgery 1, 2
Antibiotic Selection When Indicated
- The World Society of Emergency Surgery recommends carbapenems (meropenem or imipenem/cilastatin) as first-line antibiotics for confirmed infected necrosis due to their excellent pancreatic tissue penetration and broad coverage 5, 2
- Piperacillin/tazobactam is an alternative antibiotic that provides coverage against gram-negative, gram-positive, and anaerobic organisms, as suggested by the World Society of Emergency Surgery 5
Duration of Therapy
- The World Society of Emergency Surgery recommends limiting antibiotic duration to 7-14 days maximum if adequate source control (drainage) is achieved, to minimize the risk of resistant organisms and fungal infections 4, 7
- The American College of Gastroenterology suggests that antibiotics should not be continued beyond 7-14 days without documented persistent infection on culture, to avoid unnecessary antibiotic use 4, 7
Special Considerations
- Prophylactic antibiotics are recommended before ERCP in the setting of pancreatitis, as suggested by the American Society for Gastrointestinal Endoscopy 6
- Antifungal therapy (liposomal amphotericin B or echinocandin) should be considered only in high-risk patients, although routine prophylactic antifungals are not recommended, according to the Infectious Diseases Society of America 1, 5